| name | endo-paget-repeat-xray-osteolytic-lesions |
| description | This skill outlines when to obtain a repeat radiograph approximately one year after radiological diagnosis of osteolytic lesions in Paget's disease to assess lesion improvement or worsening. Consider repeat imaging if biochemical markers of bone turnover remain elevated or bone pain persists despite therapy. |
Repeat radiograph to monitor osteolytic lesions
STEP 1 — Gather Information
Collect baseline plain radiograph confirming an osteolytic lesion, date of radiological diagnosis, current biochemical markers (serum ALP, P1NP, CTx/NTx), presence of bone pain, and current antiresorptive therapy. Proceed to assess timing since diagnosis.
STEP 2 — Rule In / Rule Out
Determine whether a definitive osteolytic lesion of Paget’s disease is present on the baseline radiograph. If yes, proceed to step 3; if no, consider alternative diagnoses and do not schedule repeat X‑ray for Paget’s lesion monitoring.
STEP 3 — Classify or Stratify
Assess whether approximately 12 months have elapsed since the radiological diagnosis. If yes, proceed to step 4; if less than 12 months, obtain a repeat X‑ray only if biochemical markers are persistently elevated or bone pain has worsened.
STEP 4 — Decide
Obtain a repeat radiograph of the affected region. If the lesion shows improvement, continue current therapy and schedule the next X‑ray in 1–2 years if markers remain stable; if the lesion shows worsening or no change, consider intensifying antiresorptive therapy or investigating alternative causes; if biochemical markers remain elevated or bone pain persists despite stable imaging, consider earlier repeat imaging or additional workup.
Clinical Guardrails / Mimics / Pitfalls
Do not repeat X‑ray solely on the basis of normal alkaline phosphatase when bone pain persists; avoid using radiographs to monitor diffuse polyostotic disease without focal lesions; do not delay repeat imaging beyond 2 years if markers rise or pain develops; do not substitute plain X‑ray for bone scintigraphy when assessing overall disease extent.
Concrete Clinical Example
A 70‑year‑old woman with an osteolytic lesion in the iliac crest diagnosed 14 months ago, on oral alendronate, reports mild aching pain and has an elevated ALP (120 U/L). Repeat pelvic X‑ray shows no significant change in lesion size; she is switched to intravenous zoledronate and her symptoms improve.
Source: Paget’s Disease of Bone: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, doi:10.1210/jc.2014-2910
